Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024 [Yahoo! Finance]
LeMaitre Vascular, Inc. (LMAT)
Last lemaitre vascular, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
lemaitre.gcs-web.com/investor-relations
Company Research
Source: Yahoo! Finance
reported financial results for the fourth quarter and full year ended December 31, 2023. Business Highlights: Achieved strong annual revenue growth for both proprietary product lines, with sales increasing for SimpliDerm by 38% and CanGaroo by 3.4%. Submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (“FDA” or “Agency”) for CanGarooRM, Elutia's next-generation drug-eluting biomatrix product. FDA review and interaction for CanGarooRM has resulted in no requests for additional data to date. The Company remains on track for a clearance decision in the first half of 2024. Successfully closed the divestiture of the orthobiologics business, generating gross cash proceeds of $14.6 million. Established a Strategic Advisory Committee of industry experts to prepare for commercial launch of CanGarooRM. "After years of pioneering development, we are on the verge of introducing the drug-eluting biomatrix that promises to remove compromise from patient c
Show less
Read more
Impact Snapshot
Event Time:
LMAT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LMAT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LMAT alerts
High impacting LeMaitre Vascular, Inc. news events
Weekly update
A roundup of the hottest topics
LMAT
News
- LeMaitre Vascular, Inc. (NASDAQ: LMAT) was upgraded by analysts at Roth Capital to a "strong-buy" rating.MarketBeat
- LeMaitre Vascular, Inc. (NASDAQ: LMAT) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $100.00 price target on the stock.MarketBeat
- LeMaitre to Present at the Jefferies Global Healthcare ConferenceGlobeNewswire
- Why You Might Be Interested In LeMaitre Vascular, Inc. (NASDAQ:LMAT) For Its Upcoming Dividend [Yahoo! Finance]Yahoo! Finance
- LeMaitre Vascular, Inc. (NASDAQ: LMAT) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
LMAT
Earnings
- 5/2/24 - Beat
LMAT
Sec Filings
- 6/3/24 - Form 4
- 6/3/24 - Form 4
- 6/3/24 - Form 4
- LMAT's page on the SEC website